

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: AP1/21 - Antithrombotic Agents

Deadline: 02.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set 1</b>														
<b>(108) Apixaban</b>														
Samples and groups		[µg/L]				32						32	28	88%
<b>Sample A1</b>							CVP							
(38) IL		65,3	11	16	32		65,3	4,6	32%	44,4	86,2	32	28	88%
(94) Stago		71,9	3,1	4,3	10	0						10		
(193) HYPHEN BioMed		63,0	7,4	12	6	0						6		
Other		63,2	13	20	12	0						12		
					4	0						4		
							2x 149, 2x 179							
<b>Sample B1</b>							CVP							
(38) IL		272	25	9,3	32		272	11	25%	204	340	32	32	100%
(94) Stago		287	10	3,5	10	0						10		
(193) HYPHEN BioMed		286	10	3,6	6	0						6		
Other		256	26	10	12	0						12		
					4	0						4		
							2x 149, 2x 179							
<b>Set 2</b>														
<b>(109) Dabigatran</b>														
Samples and groups		[µg/L]				33						33	31	94%
<b>Sample A2</b>							CVP							
(38) IL		51,5	8,5	16	33		51,5	3,6	32%	35	68	33	31	94%
(149) Siemens (Dade, BN, Dimension)		51,4	3,8	7,4	10	0						10		
(193) HYPHEN BioMed		49,1	1,6	3,3	5	0						5		
Other		53,2	13	24	15	0						15		
					3	0						3		
							1x 94, 2x 179							
<b>Sample B2</b>							CVP							
(38) IL		215	26	12	33		215	11	25%	161	269	33	33	100%
(149) Siemens (Dade, BN, Dimension)		206	14	6,7	10	0						10		
(193) HYPHEN BioMed		189	13	6,8	5	0						5		
Other		236	25	11	15	0						15		
					3	0						3		
							1x 94, 2x 179							
<b>Set 3</b>														
<b>(110) Rivaroxaban</b>														
Samples and groups		[µg/L]				38						38	36	95%
<b>Sample A3</b>							CVP							
(38) IL		72,9	7,7	11	38		72,9	3,0	25%	54,6	91,2	38	36	95%
(94) Stago		75,0	4,0	5,3	12	0						12		
(193) HYPHEN BioMed		71,0	5,9	8,4	6	0						6		
Other		73,9	13	17	15	0						15		
					5	0						5		
							2x 149, 3x 179							
<b>Sample B3</b>							CVP							
(38) IL		311	24	7,9	38		311	9,7	25%	233	389	38	38	100%
(94) Stago		288	10	3,5	12	0						12		
(193) HYPHEN BioMed		314	17	5,4	6	0						6		
Other		326	19	5,8	15	0						15		
					5	0						5		
							2x 149, 3x 179							

st\_kn\_p

End of report

Printed: 09.04.2021